Recurrent Pleomorphic Adenoma of the Parotid Gland: Proposal for an LMCG Classification System and an Optimized Therapeutic Algorithm
Oral Diseases · 2025
DOI: 10.1111/odi.70022 ↗At a glance
Journal article in Oral Diseases, 2025. Written by Qicheng Ye and 6 co-authors. Institution: Department of Oral and Maxillofacial-Head and Neck Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Coll…. Major MEDLINE topics: Adenoma, Pleomorphic, Parotid Neoplasms, Neoplasm Recurrence, Local. 27 references. Funded by: Biobank Project of Shanghai Ninth People's Hospital.
Abstract (original language)
Objectives
To introduce a novel clinical classification system and corresponding therapeutic strategies for parotid recurrent pleomorphic adenoma (RPA).
Methods
A retrospective analysis was conducted on parotid RPA cases treated by a single surgical team at Shanghai Ninth People's Hospital between January 2020 and December 2024. Based on tumor features—such as single or multiple nodules, infringement of adjacent structures, or skip metastases—as well as intraoperative facial nerve status, a classification system and corresponding treatment strategy were proposed.
Results
A total of 66 patients were included in the study. The majority (95.5%) presented with multinodular tumors, and 66.7% developed facial paralysis due to intraoperative facial nerve injury. The classification system termed “Localized–Moderate–Complicated–General” (LMCG) was first developed. The Localized type represents the least severe condition, while the subsequent categories reflect progressively more complex presentations. Each classification corresponds to a tailored therapeutic strategy, ranging from partial parotidectomy with or without facial nerve preservation to extensive parotidectomy combined with immediate nerve reconstruction and adjuvant radiotherapy.
Conclusion
The LMCG classification offers a concise framework for preoperative assessment and personalized treatment planning in patients with parotid RPA, with the potential to standardize and improve its clinical outcomes.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Department of Oral and Maxillofacial-Head and Neck Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, College of Stomatology, Shanghai Jiao Tong University, National Center for…
- Department of Stomatology, Fengcheng Hospital, Fengxian District, Shanghai, China.
- Wuxi School of Medicine, Jiangnan University, Wuxi, Jiangsu, China.
ORCID profiles: Wanlin Xu
Funding
- Biobank Project of Shanghai Ninth People's Hospital
Cite
APA
Ye, Q., Liu, D., Huang, L., Zhu, W., Lu, H., Yang, W., & Xu, W. (2025). Recurrent Pleomorphic Adenoma of the Parotid Gland: Proposal for an LMCG Classification System and an Optimized Therapeutic Algorithm. Oral Diseases. https://doi.org/10.1111/odi.70022
Vancouver
Ye Q, Liu D, Huang L, Zhu W, Lu H, Yang W, et al. Recurrent Pleomorphic Adenoma of the Parotid Gland: Proposal for an LMCG Classification System and an Optimized Therapeutic Algorithm. Oral Diseases. 2025. doi:10.1111/odi.70022
BibTeX
@article{Ye2025,
author = {Ye, Qicheng and Liu, Dongrui and Huang, Lingli and Zhu, Wenya and Lu, Hao and Yang, Wenjun and Xu, Wanlin},
title = {Recurrent Pleomorphic Adenoma of the Parotid Gland: Proposal for an LMCG Classification System and an Optimized Therapeutic Algorithm},
journal = {Oral Diseases},
year = {2025},
doi = {10.1111/odi.70022}
}
EUVIMED